Lexeo Therapeutics (LXEO) Share-based Compensation (2022 - 2026)

Lexeo Therapeutics has reported Share-based Compensation for 5 years, with the latest figure at $2.8 million in Q1 2026.

• Quarterly Share-based Compensation fell 25.48% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.2 million (down 19.15% YoY) and the FY2025 annual result came in at $12.1 million, down 2.74% from the prior year.
• Share-based Compensation rose to $2.8 million in Q1 2026 per LXEO's latest filing, from $2.7 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $3.8 million in Q3 2024 and troughed at $397000.0 in Q1 2023.
• A 5-year average of $2.1 million and a median of $2.7 million in 2025 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 487.15% in 2024, then slumped 30.05% in 2025.
• Over 5 years, Share-based Compensation stood at $521000.0 in 2022, then surged by 54.32% to $804000.0 in 2023, then soared by 336.19% to $3.5 million in 2024, then slipped by 22.64% to $2.7 million in 2025, then rose by 1.55% to $2.8 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $2.8 million, $2.7 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.